Searches spiking for these stocks today
Biotech stocks are making waves today with a surge in search activity, as reported by InvestingChannel. Some of the companies experiencing a significant increase in interest include Galmed Pharmaceuticals, Protagenic Therapeutics, Hepion Pharmaceuticals, Rigel Pharmaceuticals, Bolt Biotherapeutics, Palatin Technologies, Krystal Biotech, CorMedix, Bio-Techne Corporation, and Jazz Pharmaceuticals.
Galmed Pharmaceuticals is focusing on developing Aramchol for liver and fibro-inflammatory diseases, particularly for non-alcoholic steatohepatitis (NASH) and Primary Sclerosing Cholangitis (PSC). Protagenic Therapeutics is working on neuro-active peptides to address stress-related disorders. Hepion Pharmaceuticals is developing treatments for non-alcoholic steatohepatitis and hepatocellular carcinoma. Rigel Pharmaceuticals is dedicated to improving the lives of patients with hematologic disorders and cancer. Bolt Biotherapeutics is developing novel immunotherapies for cancer treatment. Palatin Technologies is working on first-in-class medicines based on melanocortin receptor systems. Krystal Biotech is focused on genetic medicines for diseases with high unmet medical needs. CorMedix is developing therapeutic products for life-threatening conditions. Bio-Techne Corporation provides tools and reagents for research and clinical diagnostics. Jazz Pharmaceuticals is dedicated to developing life-changing medicines for patients with serious diseases.
Recent news on these stocks includes Palatin Technologies announcing new preclinical data on its melanocortin agonists, Bolt Biotherapeutics hosting a key opinion leader conference call, Hepion Pharmaceuticals entering into a licensing agreement for diagnostic tests, Bio-Techne reporting better-than-expected earnings, Galmed Pharmaceuticals announcing positive oncology study results, Rigel Pharmaceuticals reporting upbeat Q1 results, Krystal Biotech reporting mixed Q1 results, Truist raising its price target on CorMedix, and Jazz Pharmaceuticals reporting downbeat Q1 results.
These developments highlight the innovative work being done in the biotech sector and the potential impact on patient outcomes. Stay tuned for more updates on these companies as they continue to make strides in the field of biotechnology.
